(Q44289303)

1 December 2017

title

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics (English)

1 reference

1 December 2017

7

Keith T Flaherty

1 reference

1 December 2017

Jane Fridlyand

1

1 reference

1 December 2017

Richard M Simon

2

1 reference

1 December 2017

Jessica C Walrath

3

1 reference

1 December 2017

Nancy Roach

4

1 reference

1 December 2017

Richard Buller

5

1 reference

1 December 2017

David P Schenkein

6

1 reference

1 December 2017

Jeff D Allen

8

1 reference

1 December 2017

Ellen V Sigal

9

1 reference

1 December 2017

Howard I Scher

10

1 reference

1 December 2017

publication date

6 September 2013

1 reference

Nature Reviews Drug Discovery

1 December 2017

published in

1 reference

1 December 2017

volume

12

1 reference

1 December 2017

issue

10

1 reference

1 December 2017

page(s)

743-755

1 reference

Imatinib mesylate--a new oral targeted therapy

1 December 2017

cites work

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

31 March 2020

1 reference

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

31 March 2020

1 reference

Systemic therapy for advanced pancreatic neuroendocrine tumors

31 March 2020

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

31 March 2020

1 reference

Challenges in the codevelopment of companion diagnostics.

31 March 2020

1 reference

Integrating predictive biomarkers and classifiers into oncology clinical development programmes

31 March 2020

1 reference

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma

31 March 2020

1 reference

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer

31 March 2020

1 reference

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

31 March 2020

1 reference

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

31 March 2020

1 reference

An industry statistician's perspective on PHC drug development.

31 March 2020

1 reference

Randomized phase II trial designs with biomarkers

31 March 2020

1 reference

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

31 March 2020

1 reference

All-comers versus enrichment design strategy in phase II trials

31 March 2020

1 reference

Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology

31 March 2020

1 reference

Defective neuropeptide processing and ischemic brain injury: a study on proprotein convertase 2 and its substrate neuropeptide in ischemic brains

31 March 2020

1 reference

O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients

31 March 2020

1 reference

Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology

31 March 2020

1 reference

A sharper Bonferroni procedure for multiple tests of significance

31 March 2020

1 reference

Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset

31 March 2020

1 reference

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

31 March 2020

1 reference

The cross-validated adaptive signature design

31 March 2020

1 reference

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

31 March 2020

1 reference

Stratification of randomization is not required for a pre-specified subgroup analysis

31 March 2020

1 reference

Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics

31 March 2020

1 reference

Use of archived specimens in evaluation of prognostic and predictive biomarkers

31 March 2020

1 reference

Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group.

31 March 2020

1 reference

Implementing personalized cancer genomics in clinical trials

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD4101

1 reference

1 December 2017

1 reference